Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share

Equities analysts predict that Akari Therapeutics PLC (NASDAQ:AKTX) will post earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks. Zero analysts have issued estimates for Akari Therapeutics’ earnings. Akari Therapeutics posted earnings per share of ($0.08) during the same quarter last year, which indicates a negative year over year growth rate of 1,150%. The firm is expected to announce its next quarterly earnings report on Friday, March 30th.

According to Zacks, analysts expect that Akari Therapeutics will report full year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.55). For the next financial year, analysts expect that the business will post earnings of ($3.00) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Akari Therapeutics.

Several equities analysts have recently weighed in on AKTX shares. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Zacks Investment Research upgraded Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 price objective on the stock in a report on Monday, November 13th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price objective on shares of Akari Therapeutics in a report on Friday, September 22nd. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Chardan Capital reiterated a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $7.50.

Shares of Akari Therapeutics (NASDAQ:AKTX) traded up $0.01 on Tuesday, reaching $4.43. The company’s stock had a trading volume of 116,959 shares, compared to its average volume of 377,272. Akari Therapeutics has a 12-month low of $3.18 and a 12-month high of $22.20. The company has a market capitalization of $52.05, a PE ratio of -15.82 and a beta of -9.06.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd raised its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 151,334 shares of the biopharmaceutical company’s stock after acquiring an additional 91,322 shares during the period. Hikari Power Ltd owned about 1.28% of Akari Therapeutics worth $929,000 as of its most recent filing with the SEC. 20.95% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Akari Therapeutics (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit